School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Endocrinology and Metabolism Population Sciences Institute, Non-Communicable Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran.
BMC Cardiovasc Disord. 2024 Nov 26;24(1):681. doi: 10.1186/s12872-024-04350-8.
Contrast-induced acute kidney injury (CI-AKI) is one of the complications of percutaneous coronary intervention (PCI) with high financial burden and poor outcomes. Dynamic coronary roadmap (DCR) is one of the augmentation tools that can provide a dynamic clear coronary mapping with the potential to reduce contrast use and CI-AKI incidence. Herein, we aim to systematically investigate the studies that have assessed the effect of DCR on PCI outcomes.
Four online databases including PubMed, Scopus, Embase, and the Web of Science were systematically searched for relevant studies. Studies that compared the DCR group with the non-DCR group were included while the outcomes were AKI incidence, contrast volume, fluoroscopy time, dose area product, air kerma, intravascular ultrasonography (IVUS) use, and procedural success. Random-effect meta-analysis was conducted to calculate the standardized mean difference (SMD) or odds ratio (OR) and 95% confidence interval (CI) for comparison of DCR and non-DCR groups.
A total of six studies were included in the final analysis comprised of 447 patients in the DCR group and 527 in the non-DCR group. The mean age was 68.7 ± 10.6 years while 78.9% of the DCR group and 75.6% of the non-DCR group were males. There was no difference between the groups in terms of the rates of hypertension, diabetes, hyperlipidemia, prior myocardial infarction (MI), prior coronary artery bypass grafting (CABG), and atrial fibrillation. Meta-analysis revealed that patients in the DCR group had a significantly lower rate of AKI (OR 0.50, 95% CI 0.27 to 0.93, p-value = 0.028), and contrast volume used (SMD -1.16, 95% CI -2.15 to -0.18, p-value = 0.021). However, there was no difference in fluoroscopy time (SMD -0.64, 95% CI -1.43 to 0.16, p-value = 0.116), air kerma (SMD -1.81, 95% CI -4.61 to 0.99, p-value = 0.206), IVUS use (OR 1.21, 95% CI 0.85 to 1.73, p-value = 0.285), and procedural success (OR 1.05, 95% CI 1.15 to 7.26, p-value = 0.957).
These findings show that DCR use is associated with a lower rate of AKI and lower contrast use, compared to conventional PCI. This is of particular importance since many patients undergoing PCI have limited renal function and hence will benefit from the use of DCR. Further studies are needed to confirm these findings and to pave the way for the routine use of DCR in clinical settings.
对比剂诱导的急性肾损伤(CI-AKI)是经皮冠状动脉介入治疗(PCI)的并发症之一,具有较高的经济负担和较差的预后。动态冠状动脉造影图(DCR)是一种增强工具,它可以提供动态清晰的冠状动脉映射,具有降低对比剂使用和 CI-AKI 发生率的潜力。在此,我们旨在系统地评估 DCR 对 PCI 结果的影响。
我们系统地检索了包括 PubMed、Scopus、Embase 和 Web of Science 在内的四个在线数据库,以获取相关研究。我们纳入了比较 DCR 组和非 DCR 组的研究,结局指标包括 AKI 发生率、对比剂用量、透视时间、剂量面积乘积、空气比释动能、血管内超声(IVUS)使用和手术成功率。采用随机效应荟萃分析计算标准化均数差(SMD)或比值比(OR)和 95%置信区间(CI)以比较 DCR 组和非 DCR 组。
最终有六项研究被纳入分析,其中 DCR 组有 447 例患者,非 DCR 组有 527 例患者。平均年龄为 68.7±10.6 岁,DCR 组和非 DCR 组中分别有 78.9%和 75.6%的患者为男性。两组在高血压、糖尿病、高脂血症、既往心肌梗死(MI)、既往冠状动脉旁路移植术(CABG)和心房颤动的发生率方面无差异。荟萃分析显示,DCR 组 AKI 发生率显著降低(OR 0.50,95%CI 0.27 至 0.93,p 值=0.028),且对比剂用量也减少(SMD -1.16,95%CI -2.15 至 -0.18,p 值=0.021)。然而,透视时间(SMD -0.64,95%CI -1.43 至 0.16,p 值=0.116)、空气比释动能(SMD -1.81,95%CI -4.61 至 0.99,p 值=0.206)、IVUS 使用(OR 1.21,95%CI 0.85 至 1.73,p 值=0.285)和手术成功率(OR 1.05,95%CI 1.15 至 7.26,p 值=0.957)两组间无差异。
与常规 PCI 相比,DCR 的使用与 AKI 发生率降低和对比剂用量减少相关。对于许多接受 PCI 的肾功能有限的患者来说,这一点尤其重要,因为他们将受益于 DCR 的使用。需要进一步的研究来证实这些发现,并为 DCR 在临床环境中的常规使用铺平道路。